Compare NeoGenomics Inc. Common Stock (NEO) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NeoGenomics Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: NeoGenomics Inc. Common Stock is the larger of the two by market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NEO | QURE | |
|---|---|---|
Market Cap | $2.17B | $1.45B |
Volume | 1,615,943 | 3,323,243 |
Sector | Health | Health |
52-Week High | $19.91 | $70.59 |
52-Week Low | $7.19 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.47B | $707.46M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NeoGenomics Inc. Common Stock
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
